GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI) » Definitions » Cyclically Adjusted Book per Share

Cyclacel Pharmaceuticals (STU:UXI) Cyclically Adjusted Book per Share : €896.30 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cyclacel Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Cyclacel Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2024 was €-1.540. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €896.30 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Cyclacel Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -38.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -29.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -27.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -30.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Cyclacel Pharmaceuticals was -7.50% per year. The lowest was -41.50% per year. And the median was -29.40% per year.

As of today (2024-06-06), Cyclacel Pharmaceuticals's current stock price is €1.93. Cyclacel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €896.30. Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cyclacel Pharmaceuticals was 0.50. The lowest was 0.01. And the median was 0.04.


Cyclacel Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Cyclically Adjusted Book per Share Chart

Cyclacel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,410.72 2,864.88 2,057.48 1,585.19 1,117.10

Cyclacel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,575.31 1,401.22 1,208.88 1,117.10 896.30

Competitive Comparison of Cyclacel Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Cyclacel Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cyclacel Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.54/131.7762*131.7762
=-1.540

Current CPI (Mar. 2024) = 131.7762.

Cyclacel Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 3,456.825 100.560 4,529.928
201409 3,035.397 100.428 3,982.892
201412 2,731.211 99.070 3,632.883
201503 2,615.183 99.621 3,459.296
201506 2,248.482 100.684 2,942.838
201509 1,996.473 100.392 2,620.617
201512 1,750.101 99.792 2,311.014
201603 1,445.040 100.470 1,895.303
201606 1,169.062 101.688 1,514.971
201609 1,065.208 101.861 1,378.045
201612 953.559 101.863 1,233.586
201703 841.643 102.862 1,078.224
201706 699.730 103.349 892.197
201709 504.770 104.136 638.751
201712 459.915 104.011 582.686
201803 413.603 105.290 517.649
201806 398.650 106.317 494.114
201809 355.689 106.507 440.079
201812 322.228 105.998 400.593
201903 270.992 107.251 332.962
201906 242.840 108.070 296.111
201909 219.396 108.329 266.882
201912 183.621 108.420 223.177
202003 164.033 108.902 198.488
202006 72.782 108.767 88.178
202009 63.984 109.815 76.780
202012 65.646 109.897 78.715
202103 65.563 111.754 77.309
202106 58.266 114.631 66.981
202109 53.827 115.734 61.288
202112 50.071 117.630 56.093
202203 45.535 121.301 49.467
202206 37.765 125.017 39.807
202209 32.092 125.227 33.771
202212 23.075 125.222 24.283
202303 16.360 127.348 16.929
202306 10.545 128.729 10.795
202309 4.777 129.860 4.848
202312 0.526 129.419 0.536
202403 -1.540 131.776 -1.540

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Cyclacel Pharmaceuticals  (STU:UXI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.93/896.3
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cyclacel Pharmaceuticals was 0.50. The lowest was 0.01. And the median was 0.04.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Cyclacel Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclacel Pharmaceuticals (STU:UXI) Business Description

Traded in Other Exchanges
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals (STU:UXI) Headlines

No Headlines